Skip to main content
Top
Published in: International Urology and Nephrology 12/2020

01-12-2020 | Anticoagulant | Nephrology - Original Paper

Application of regional citrate anticoagulation in membrane therapeutic plasma exchange

Authors: Fang Yuan, Zheng Li, Xiejia Li, Hong Liu

Published in: International Urology and Nephrology | Issue 12/2020

Login to get access

Abstract

Background

Both regional citrate anticoagulation (RCA) and heparin are used as anticoagulants during membrane therapeutic plasma exchange (mTPE). However, there are few reports of comparisons of the two methods. The aim of this study was to compare different anticoagulants in mTPE and observe the effectiveness, safety, and advantages of RCA.

Methods

We retrospectively included 85 patients who underwent mTPE in the past 1 year, and divided them into three groups. Patients with no bleeding tendency were administered heparin anticoagulation; patients with bleeding tendency/with liver dysfunction/who had undergone an operation were treated with RCA, or did not receive anticoagulation. In the heparin group, low-dose heparin anticoagulation was administered; in the RCA group, 4% sodium citrate solution was administered, and 10% calcium gluconate solution was pumped from the venous circuit tube. The peripheral blood platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), and electrolytes were detected before and after treatment in all patients.

Results

A total of 255 sessions of mTPE were performed in 85 patients (2–7 times/case) with 120 sessions of heparin anticoagulation, 93 sessions of RCA, and 42 sessions of no anticoagulation. Compared with pretreatment values, the platelet count decreased by 53.7% and the PT and APTT increased (p < 0.05) in the heparin group after treatment. There were no differences in platelet count and PT before and after treatment in the RCA group. In the RCA group, the patients did not experience hypocalcemia or hypercalcemia, and no separator clotting occurred.

Conclusion

RCA is safe, feasible, and effective in mTPE, especially for patients with bleeding tendency and frequent monitoring is needed. It is worth widely developing and applying it in clinical practice.
Literature
1.
go back to reference Chen X, Chen N (2013) Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 181:240–247CrossRef Chen X, Chen N (2013) Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 181:240–247CrossRef
2.
go back to reference Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y (2014) Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 18(1):41–49CrossRef Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y (2014) Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 18(1):41–49CrossRef
3.
go back to reference Láinez-Andrés JM, Gascón-Giménez F, Coret-Ferrer F, Casanova-Estruch B, Santonja JM (2015) Therapeutic plasma exchange: applications in neurology. Rev Neurol 60(3):120–131PubMed Láinez-Andrés JM, Gascón-Giménez F, Coret-Ferrer F, Casanova-Estruch B, Santonja JM (2015) Therapeutic plasma exchange: applications in neurology. Rev Neurol 60(3):120–131PubMed
4.
go back to reference Kindgen-Milles D, Brandenburger T, Dimski T (2018) Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 24(6):450–454CrossRef Kindgen-Milles D, Brandenburger T, Dimski T (2018) Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 24(6):450–454CrossRef
5.
go back to reference Janssen MJ (1996) The bleeding risk in chronic haemodialysis. Preventive strategies in high-risk patients. Neth J Med 48:198–207CrossRef Janssen MJ (1996) The bleeding risk in chronic haemodialysis. Preventive strategies in high-risk patients. Neth J Med 48:198–207CrossRef
6.
go back to reference Lee G, Arepally GM (2012) Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Clin Apher 27(3):117–125CrossRef Lee G, Arepally GM (2012) Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Clin Apher 27(3):117–125CrossRef
7.
go back to reference Maharaj S, Chang S, Seegobin K, Morales J, Aysola A, Rana F, Shaikh M (2018) Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol 7:23CrossRef Maharaj S, Chang S, Seegobin K, Morales J, Aysola A, Rana F, Shaikh M (2018) Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol 7:23CrossRef
8.
go back to reference Mollison PL (2000) The introduction of citrate as an anticoagulant for transfusion and of glucose as a red cell preservative. Br J Haematol 108:13–18CrossRef Mollison PL (2000) The introduction of citrate as an anticoagulant for transfusion and of glucose as a red cell preservative. Br J Haematol 108:13–18CrossRef
9.
go back to reference Oudemans-van Straaten HM, Fiaccadori E, Baldwin I (2010) Anticoagulation for renal replacement therapy: different methods to improve safety. Contrib Nephro 165:251–262CrossRef Oudemans-van Straaten HM, Fiaccadori E, Baldwin I (2010) Anticoagulation for renal replacement therapy: different methods to improve safety. Contrib Nephro 165:251–262CrossRef
10.
go back to reference Antonic M, Gubensek J, Buturović-Ponikvar J, Ponikvar R (2009) Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 13(4):322–326CrossRef Antonic M, Gubensek J, Buturović-Ponikvar J, Ponikvar R (2009) Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 13(4):322–326CrossRef
11.
go back to reference van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:45–50 van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:45–50
12.
go back to reference Monchi M (2017) Citrate pathophysiology and metabolism. Transfus Apher Sci 56(1):28–30CrossRef Monchi M (2017) Citrate pathophysiology and metabolism. Transfus Apher Sci 56(1):28–30CrossRef
13.
go back to reference Uhl L, Maillet S, King S, Kruskall MS (1997) Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 37:1063–1065CrossRef Uhl L, Maillet S, King S, Kruskall MS (1997) Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 37:1063–1065CrossRef
14.
go back to reference Hester JP, McCullough J, Mishler JM, Szymanski IO (1983) Dosage regimens for citrate anticoagulants. J Clin Apher 1:149–157CrossRef Hester JP, McCullough J, Mishler JM, Szymanski IO (1983) Dosage regimens for citrate anticoagulants. J Clin Apher 1:149–157CrossRef
15.
go back to reference Sigler K, Lee J, Srivaths P (2018) Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher 33(3):274–277CrossRef Sigler K, Lee J, Srivaths P (2018) Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher 33(3):274–277CrossRef
16.
go back to reference Crookston KP, Novak DJ (2010) Physiology of apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL (eds) Apheresis: principles and practice. AABBPress, Bethesda, pp 45–69 Crookston KP, Novak DJ (2010) Physiology of apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL (eds) Apheresis: principles and practice. AABBPress, Bethesda, pp 45–69
17.
go back to reference Marques MB, Huang ST (2001) Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher 16:120–124CrossRef Marques MB, Huang ST (2001) Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher 16:120–124CrossRef
18.
go back to reference Wright S, Steinwandel U, Ferrari P (2011) Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 16(4):396–402CrossRef Wright S, Steinwandel U, Ferrari P (2011) Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 16(4):396–402CrossRef
19.
go back to reference Weiss R, Fischer MB, Weber V (2017) The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis. J Clin Apher 32(6):375–383CrossRef Weiss R, Fischer MB, Weber V (2017) The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis. J Clin Apher 32(6):375–383CrossRef
20.
go back to reference Puppe B, Kingdon EJ (2014) Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit. Clin Kidney J 7:201–205CrossRef Puppe B, Kingdon EJ (2014) Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit. Clin Kidney J 7:201–205CrossRef
21.
go back to reference Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D (2017) Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol 31(3):387–401CrossRef Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D (2017) Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol 31(3):387–401CrossRef
22.
go back to reference Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39:350–354CrossRef Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39:350–354CrossRef
Metadata
Title
Application of regional citrate anticoagulation in membrane therapeutic plasma exchange
Authors
Fang Yuan
Zheng Li
Xiejia Li
Hong Liu
Publication date
01-12-2020
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 12/2020
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-020-02581-0

Other articles of this Issue 12/2020

International Urology and Nephrology 12/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.